<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OXAMNIQUINE</span><br/>(ox-am'ni-kwin)<br/><span class="topboxtradename">Vansil<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">anthelmintic</span><br/><b>Prototype: </b>Mebendazole<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Hydroquinone derivative prepared in the presence of <i>Aspergillus sclerotium</i>. Mechanism of action not fully explained, but it appears that drug-induced strong contractions and paralysis of worm musculature
         leads to immobilization of their suckers and dislodgment from their usual residence in mesenteric veins to the liver.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Dislodgment of schistosomes begins about 2 d after single oral dose; movement is not complete until 6 d after treatment with
         the drug. After treatment, surviving unpaired females return to mesenteric vessels; however, oviposition (egg laying) seems
         to stop in 2448 h after drug treatment, reducing egg load and removing principal cause of pathology associated with
         schistosomal infection.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>All stages of <i>Schistosoma mansoni</i> infection, including acute and chronic phases with hepatosplenic involvement.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Safe use during pregnancy (category C), lactation, or in children is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of convulsant disorders.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Schistosomiasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1215 mg/kg as single dose<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 30 kg, 10 mg/kg times 2 doses at 28 h intervals<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on an empty stomach, if possible.</li>
<li>Administer with food if necessary to reduce GI distress and improve tolerance.</li>
<li>Store product in tightly closed container at controlled room temperature less than 30° C (86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Transitory dizziness, drowsiness, headache;</span> persistent fever (in patients being treated in Egypt); EEG abnormalities, convulsions (rare). <span class="typehead">GI:</span> Anorexia, nausea, vomiting, abdominal pain, elevated liver enzyme concentrations. <span class="typehead"> Hematologic:</span>  Increased erythrocyte sedimentation rate, reticulocyte count, and increased or decreased leukocyte count. <span class="typehead">Skin:</span> Urticaria. <span class="typehead">Urogenital:</span> Red-orange urine. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Food:</span> Rate and extent of absorption are decreased by food. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 13 h. <span class="typehead">Metabolism:</span> Extensively metabolized in GI mucosa. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 12.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Supervise ambulation and use other safety precautions because &gt;30% of patients experience dizziness or drowsiness.</li>
<li>If patient has a history of seizures, the possibility of seizures is increased because of drug action (occurs within hours
            of drug administration).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use caution while driving or performing other tasks requiring alertness because drug can cause dizziness or drowsiness.</li>
<li>Be aware that drug may change the normal urine color to a harmless orange-red.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>